Life Sciences Update | 2022 October
Future Demand
U.S. Novel Drug and Biological Approvals, FDA
Number of Clinical Trials By Market
Clinical Trials by Type
8,000
Novel Drug Approvals Biologicals
7,000
90
6,000
80
Other 25%
5,000
70
4,000
60
3,000
50
Drug 54%
2,000
40
Device 10%
1,000
30
0
20
Biological 11%
10
0
2015 2016 2017 2018 2019 2020 2021 2022YTD
Source: U.S. Food and Drug Administration
Source: Clinicaltrials.gov
In the U.S., when companies receive FDA approval, they need to quickly move into a manufacturing capacity. The FDA has worked to improve their approval processes and have, over time, increased the number of approvals for novel drugs and biologicals. 1 Although 2022 appears to be behind the uptick in approvals of the last four years, drug-related clinical trials account for 54% of the current trials in the U.S., indicating a robust pipeline of activity for future FDA approvals.
Drug trials account for 54% of clinical trials across the markets that Cushman & Wakefield tracks. Biological and device trials account for 11% and 10% of clinical trials, respectively. All other trials, including behavioural and diagnostic testing, make up the remaining 25%. The top five markets with the greatest number of clinical trials currently include New York, Boston, Los Angeles, Philadelphia and Chicago. These markets boast some of the largest hospital systems and medical universities, where many of these clinical trials take place.
1 Vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products.
16 / CUSHMAN & WAKEFIELD
LIFE SCIENCES UPDATE | 2022 OCTOBER
Made with FlippingBook - Online magazine maker